BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, December 2, 2024
See today's BioWorld Asia
Home
» Gennbio licenses in two immunosuppressants valued up to $164M from Genexine
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Gennbio licenses in two immunosuppressants valued up to $164M from Genexine
Jan. 14, 2020
By
Jihyun Kim
No Comments
Gennbio Co. Ltd. has signed an agreement with fellow Korean biotech Genexine Inc. to in-license two immunosuppressant drug candidates called GX-P1 (PD-L1 hyfc) and BSF-110 (PD-L1-hyFc-1L10m).
BioWorld Asia
Deals and M&A
Immune
Asia-Pacific
